Search for: "Wyeth Laboratories Inc" Results 121 - 140 of 200
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
28 May 2020, 5:29 am by Schachtman
Relying upon pre-2000 Ninth Circuit case law, decided before the statutory language of Rule 702 was adopted, the court found that: “expert evidence is inadmissible where the analysis is the result of a faulty methodology or theory as opposed to imperfect execution of laboratory techniques whose theoretical foundation is sufficiently accepted in the scientific community to pass muster under Daubert. [read post]
9 Apr 2015, 5:00 am
  Two other state supreme courts have reaffirmed the learned intermediary rule since then, Wyeth, Inc. v. [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
15 Jul 2009, 5:15 am
IPAB rejects Novartis’ patent application for Glivec (Intellectual Property Watch) Lescol (Fluvastatin) – Netherlands: No interim relief pending appeal against invalidity, rules District Court of The Hague: Novartis v Mylan and Actavis (PatLit) Levaquin (Levoflaxacin) – Canada: FCA holds generics raising allegations similar to those of previous generics allowed their day in court: Apotex v Janssen-Ortho (Global IP Watch) Lexapro (Escitalopram) – US: Caraco… [read post]
2 Sep 2010, 8:35 am by Stefanie Levine
  Filed August 2, 2010 by Dolby Laboratories, Inc. (3)  95/000,563 (paper filed) – U.S. [read post]
12 Mar 2024, 12:46 pm by admin
Wyeth-Ayerst Laboratories Co., 278 F.Supp.2d 684, 700 (W.D.N.C. 2003) (expert witnesses may not opine about corporate intent and motive) (barring Dr. [read post]
13 May 2010, 12:27 pm by Bexis
Wyeth, Inc., 2010 WL 450351 (W.D. [read post]
5 Jun 2013, 5:29 am by Schachtman
Merrill-National Laboratories, 646 F.Supp. 856 (D. [read post]
16 Mar 2012, 5:00 am by Bexis
Automated Medical Laboratories, Inc., 471 U.S. 707, 715-18 (1985)), there’s not a peep about the elusive presumption in Kurns. [read post]
27 Jan 2010, 3:00 am
- ‘indirect consumer tax’ to fund UN public health initiatives (Afro-IP) Canada: Submissions on Canada-EU trade deal: Canadian Generic Pharma Assoc. wants IP out (Michael Geist) Canada: Intellectual property and agriculture – CDC Triffid seed story (ipblog.ca) EU: Records of the 1st, 2nd and 3rd expert meetings on SPCs (The SPC Blog) EU: Cooperation between Board of Appeal and National Court / acceleration of appeal proceedings: Human Genome Sciences v Eli Lilly (EPLAW) Indian… [read post]
23 Sep 2010, 11:56 am by Bexis
Wyeth-Ayerst Laboratories, 385 F.3d 961 (6th Cir. 2004)]. . . . [read post]
23 Dec 2007, 8:00 pm
You can separately subscribe to the IP Thinktank Global week in Review at [feeds.feedburner.com]GlobalEvents in Bali heap further pressure on all IP owners: (IAM),Velcro defies generic claim in domain name battle: (OUT-LAW),ICANN forms group to hasten non-English domain names: (IP Justice)WTO members continue debate on geographical indications register: (Intellectual Property Watch),Creative Commons launches CCo and CC programs: (World IP Day),Green IP Strategy - risks… [read post]